Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

24.43
-0.0928-0.38%
Volume:144
Turnover:4K
Market Cap:5.62M
PE:- -
High:24.52
Open:24.52
Low:24.43
Close:24.52
52wk High:27.94
52wk Low:22.89
Shares:230.00K
Float Shares:230.00K
Volume Ratio:0.13
T/O Rate:0.06%
Dividend:0.41
Dividend Rate:1.69%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Oct 09

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Oct 09

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Oct 09

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Oct 09

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Oct 09

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Oct 09

Novo Nordisk's Wegovy Pill to Buoy Sales, but Investors Likely to Stay Sidelined

Dow Jones
·
Oct 09

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Oct 09

Citi Lowers Novo Nordisk Price Target to DKK 296: Oral Weight-Loss Pill Sales Outlook Improves, but Margin Growth Remains Weak

Deep News
·
Oct 09

Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 4.89%

TIPRANKS
·
Oct 09

Lilly’s Oral Orforglipron Trial Targets Early Obesity Risks, Raising the Stakes in Weight-Loss Pharma

TIPRANKS
·
Oct 09

Novo Nordisk Wraps Up Real World Joint Health Study for Esperoct in Haemophilia A

TIPRANKS
·
Oct 09

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 09

1s Could Offer Unexpected Relief from Back and Knee Pain, but Doctors Urge Caution

Dow Jones
·
Oct 08

Scholar Rock Resubmits Apitegromab MAA to EMA for SMA Treatment

Reuters
·
Oct 08

Scholar Rock Holding Corporation - Anticipates Chmp Opinion on Apitegromab Maa in H1 2027

THOMSON REUTERS
·
Oct 08

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) to European Medicines Agency (Ema) for Treatment of Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
Oct 08

How to invest in healthcare stocks without picking the next Eli Lilly

Simply Wall St.
·
Oct 08

Dow Falls Over 300 Points As Treasury Yields Surge: Investor Sentiment Weakens, Fear & Greed Index Remains In ‘Neutral’ Zone

Benzinga Earnings
·
Oct 08

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 08